Systematic screening using FRAX® leads to increased use of, and adherence to, anti-osteoporosis medications: an analysis of the UK SCOOP trial
In the large community-based SCOOP trial, systematic fracture risk screening using FRAX® led to greater use of AOM and greater adherence, in women at high fracture risk, compared with usual care.
In the SCreening of Older wOmen for Prevention of fracture (SCOOP) trial, we investigated the effect of the screening intervention on subsequent long-term self-reported adherence to anti-osteoporosis medications (AOM).
SCOOP was a primary care–based UK multicentre trial of screening for fracture risk. A total of 12,483 women (70–85 years) were randomised to either usual NHS care, or assessment using the FRAX® tool ± dual-energy X-ray absorptiometry (DXA), with medication recommended for those found to be at high risk of hip fracture. Self-reported AOM use was obtained by postal questionnaires at 6, 12, 24, 36, 48 and 60 months. Analysis was limited to those who initiated AOM during follow-up. Logistic regression was used to explore baseline determinants of adherence (good ≥ 80%; poor < 80%).
The mean (SD) age of participants was 75.6 (4.2) years, with 6233 randomised to screening and 6250 to the control group. Of those participants identified at high fracture risk in the screening group, 38.2% of those on treatment at 6 months were still treated at 60 months, whereas the corresponding figure for the control group was 21.6%. Older age was associated with poorer adherence (OR per year increase in age 0.96 [95% CI 0.93, 0.99], p = 0.01), whereas history of parental hip fracture was associated with greater rate adherence (OR 1.67 [95% CI 1.23, 2.26], p < 0.01).
Systematic fracture risk screening using FRAX® leads to greater use of AOM and greater adherence, in women at high fracture risk, compared with usual care.
KeywordsAdherence Epidemiology FRAX® Medication Osteoporosis Screening
The SCOOP study was designed and done with substantial input from the Norwich Clinical Trials Unit, UK, particularly the construction of the study database and provision of online randomisation (completed by Tony Dyer). We thank Margaret McWilliams and Ann Pulford, the study’s public and patient involvement representatives, for invaluable advice and support, and our trial steering committee and data monitoring committee.
Birmingham: Nicola Crabtree, Helen Duffy, Jim Parle, Farzana Rashid, Katie Stant. Bristol: Kate Taylor, Clare Thomas (née Emmett). Manchester: Emma Knox, Cherry Tenneson, Helen Williams. Norwich: David Adams, Veronica Bion, Jeanette Blacklock, Tony Dyer. Sheffield: Selina Bratherton (née Simpson), Matt Fidler, Katharine Knight, Carol McGurk, Katie Smith, Stacey Young. Southampton: Karen Collins, Janet Cushnaghan. York: Catherine Arundel, Kerry Bell, Laura Clark, Sue Collins, Sarah Gardner, Natasha Mitchell.
This study was jointly funded by Arthritis Research UK (formerly the Arthritis Research Campaign) and the UK Medical Research Council. NMR’s time is supported by the National Institute for Health Research Collaboration for Leadership in Applied Health Research and Care West (NIHR CLAHRC West) at the University Hospitals Bristol NHS Foundation Trust.
Compliance with ethical standards
Conflicts of interest
CC has received consultancy fees and honoraria from Amgen, Danone, Eli Lilly, GlaxoSmithKline, Medtronic, Merck, Nestlé, Novartis, Pfizer, Roche, Servier, Shire, Takeda and UCB. NH has received consultancy, lecture fees and honoraria from Alliance for Better Bone Health, Amgen, MSD, Eli Lilly, Servier, Shire, UCB, Consilient Healthcare and Internis Pharma. JK has held grants from Amgen, Lilly, Unigene and Radius Health; has received non-financial support from Medimaps, Asahi and AgNovos; and is the architect of FRAX®, but has no financial interest. EM has been, or currently is, an adviser or speaker for and has received research support from ActiveSignal, Amgen, AstraZeneca, Consilient Healthcare, GlaxoSmithKline, Hologic, Internis, Eli Lilly, Medtronic, Merck, Novartis, Pfizer, Roche, Sanofi-Aventis, Servier, Synexus, Tethys, UCB and Warner Chilcott; and has received research support from I3 Innovus, International Osteoporosis Foundation and Unilever. All other authors declare no competing interests.
- 1.(1994) World Health Organization. Assessment of fracture risk and its application to screening for postmenopausal osteoporosis. WHO GenevaGoogle Scholar
- 2.Kanis JA (2007) Assessment of osteoporosis at the primary health care level. WHO Scientific Group Technical Report. World Health Organization, GenevaGoogle Scholar
- 5.Shepstone L, Fordham R, Lenaghan E, Harvey I, Cooper C, Gittoes N, Heawood A, Peters TJ, O’Neill T, Torgerson D, Holland R, Howe A, Marshall T, Kanis JA, McCloskey E (2012) A pragmatic randomised controlled trial of the effectiveness and cost-effectiveness of screening older women for the prevention of fractures: rationale, design and methods for the SCOOP study. Osteoporos Int 23:2507–2515CrossRefGoogle Scholar
- 6.Shepstone L, Lenaghan E, Cooper C et al (2017) Screening in the community to reduce fractures in older women (SCOOP): a randomised controlled trial. In: LancetGoogle Scholar
- 7.Turner DA, Khioe RFS, Shepstone L, Lenaghan E, Cooper C, Gittoes N, Harvey NC, Holland R, Howe A, McCloskey E, O'Neill TW, Torgerson D, Fordham R, the SCOOP Study Team (2018) The cost-effectiveness of screening in the community to reduce osteoporotic fractures in older women in the UK: economic evaluation of the SCOOP study. J Bone Miner Res 33:845–851CrossRefGoogle Scholar
- 8.McCloskey E, Johansson H, Harvey NC, Shepstone L, Lenaghan E, Fordham R, Harvey I, Howe A, Cooper C, Clarke S, Gittoes N, Heawood A, Holland R, Marshall T, O'Neill TW, Peters TJ, Redmond N, Torgerson D, Kanis JA, the SCOOP Study Team (2018) Management of patients with high baseline hip fracture risk by FRAX reduces hip fractures-a post hoc analysis of the SCOOP study. J Bone Miner Res 33:1020–1026CrossRefGoogle Scholar
- 13.Cauley JA, Chlebowski RT, Wactawski-Wende J, Robbins JA, Rodabough RJ, Chen Z, Johnson KC, O’Sullivan MJ, Jackson RD, Manson JE (2013) Calcium plus vitamin D supplementation and health outcomes five years after active intervention ended: the Women’s Health Initiative. J Women’s Health 22(2002):915–929CrossRefGoogle Scholar
- 14.2015 S (2015) Stata statistical software. TexasGoogle Scholar
- 19.Siris ES, Gehlbach S, Adachi JD, Boonen S, Chapurlat RD, Compston JE, Cooper C, Delmas P, Díez-Pérez A, Hooven FH, LaCroix AZ, Netelenbos JC, Pfeilschifter J, Rossini M, Roux C, Saag KG, Sambrook P, Silverman S, Watts NB, Wyman A, Greenspan SL (2011) Failure to perceive increased risk of fracture in women 55 years and older: the Global Longitudinal Study of Osteoporosis in Women (GLOW). Osteoporos Int 22:27–35CrossRefGoogle Scholar
- 20.Litwic AE, Compston JE, Wyman A et al (2017) Self-perception of fracture risk: what can it tell us? In: Osteoporos Int, vol 28, pp 3495–3500Google Scholar
- 23.van der Velde RY, Wyers CE, Curtis EM, Geusens PP, van den Bergh JP, de Vries F, Cooper C, van Staa TP, Harvey NC (2016) Secular trends in fracture incidence in the UK between 1990 and 2012. Osteoporos IntGoogle Scholar
- 24.Hawley S, Leal J, Delmestri A, Prieto-Alhambra D, Arden NK, Cooper C, Javaid MK, Judge A (2016) Anti-osteoporosis medication prescriptions and incidence of subsequent fracture among primary hip fracture patients in England and Wales: an interrupted time-series analysis. J Bone Miner Res 31:2008–2015CrossRefGoogle Scholar
- 25.Hernlund E, Svedbom A, Ivergard M, Compston J, Cooper C, Stenmark J, McCloskey EV, Jonsson B, Kanis JA (2013) Osteoporosis in the European Union: medical management, epidemiology and economic burden: a report prepared in collaboration with the International Osteoporosis Foundation (IOF) and the European Federation of Pharmaceutical Industry Associations (EFPIA). Arch Osteoporos 8:136CrossRefGoogle Scholar
- 26.Hiligsmann M, Salas M, Hughes DA, Manias E, Gwadry-Sridhar FH, Linck P, Cowell W (2013) Interventions to improve osteoporosis medication adherence and persistence: a systematic review and literature appraisal by the ISPOR Medication Adherence & Persistence Special Interest Group. Osteoporos Int 24:2907–2918CrossRefGoogle Scholar